Finance

Beta
Lists
BDX:NYSE
Becton Dickinson and Co
$145.61
+0.82%
(+1.18) 1D
$145.61
0.00% (0.00)
After hours
Closed: Jun 3, 4:00:04 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BDX...
Open
$144.46
High
$146.72
Low
$144.20
Mkt. cap
40.12B
Avg. vol.
3.19M
Volume
1.61M
Dividend
2.88%
Quarterly dividend
$1.05
Ex-dividend date
Jun 9, 2026
P/E ratio
36.97
52-wk high
$187.35
52-wk low
$127.54
EPS
$3.94
Beta
0.21
Shares outstanding
275.54M
No. of employees
72K
Open
$144.46
High
$146.72
Low
$144.20
Mkt. cap
40.12B
Avg. vol.
3.19M
Volume
1.61M
Dividend
2.88%
Quarterly dividend
$1.05
Ex-dividend date
Jun 9, 2026
P/E ratio
36.97
52-wk high
$187.35
52-wk low
$127.54
EPS
$3.94
Beta
0.21
Shares outstanding
275.54M
No. of employees
72K
Analyst outlook
Analyst Ratings
Based on 10 analysts giving stock ratings to BDX in the past 3 months
Buy
Buy
5
Hold
5
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for BDX in the last 3 months.
Highest
Current $145.61
$221.00 (+51.78%)
Average
$182.40 (+25.27%)
Lowest
$161.00 (+10.57%)
News stories
From sources across the web
Profile
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas. BD is ranked #211 in the 2024 Fortune 500 list based on its revenues for the fiscal year ending September 30, 2023. Wikipedia
About Becton Dickinson and Co
CEOThomas Polen
Employees72K
Founded1897
HeadquartersFranklin Lakes, New Jersey, United States
SectorMedical device
Websitebd.com
Last report
May 7, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$2.90 / $2.77
+4.51%beat
Revenue / Est. (USD)
4.71B / 4.67B
+0.90%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
5.51B
5.89B
4.49B
4.71B
Cost of goods sold
2.88B
3.09B
2.43B
2.56B
Cost of revenue
2.88B
3.09B
2.43B
2.56B
Research and development expenses
297.00M
322.00M
235.00M
249.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.35B
1.43B
1.23B
1.24B
Operating expense
1.65B
1.75B
1.46B
1.46B
Total operating expenses
4.53B
4.84B
3.90B
4.02B
Operating income
981.00M
1.05B
590.00M
695.00M
Other non operating income
-4.00M
92.00M
-12.00M
109.00M
EBT including unusual items
703.00M
510.00M
311.00M
39.00M
EBT excluding unusual items
830.00M
947.00M
429.00M
664.00M
Income tax expense
129.00M
17.00M
-
76.00M
Effective tax rate
18.35%
3.33%
-
194.87%
Other operating expenses
8.00M
-4.00M
1.00M
-26.00M
Net income
574.00M
493.00M
383.00M
-311.00M
Net profit margin
10.42%
8.37%
8.54%
-6.60%
Earnings per share
3.68
3.96
2.91
2.90
Interest and investment income
5.00M
5.00M
4.00M
9.00M
Interest expense
-152.00M
-155.00M
-153.00M
-149.00M
Net interest expenses
-147.00M
-150.00M
-149.00M
-140.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.60B
1.68B
1.20B
1.22B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer